Global Biomarker Technologies Market Size, Share, Forecast Report, 2020-2027

The biomarker technologies market is expected to reach USD 78 Billion by 2023 at a CAGR of 9% during the forecast period. The term biomarker is usually used to define a measurable indicator of some biological state or condition. The term is also referred to a substance whose detection indicates the presence of a living organism. In medicine, a biomarker is referred to as a traceable substance that is introduced into an organism to examine the proper functioning of any organ. In cell biology, a biomarker is used as a medium for the detection of cellular defects and isolation of a particular cell type (for example, the protein Oct-4 is used as a biomarker to identify embryonic stem cells). In genetics, a biomarker or genetic marker is a stretch of DNA sequence or oligonucleotide sequence that can be used to create genetic maps of whatever organism is being studied. Biomarkers are used for diagnosis and clinical decision making in cancer, diabetes, cardiovascular, and neurological diseases. The market for biomarker technologies is expanding worldwide under the influence of factors such as increased incidences of above diseases, advances in the area of medical technologies, governmental initiatives supporting research in the area of biomarker technologies, and increasing use of biomarkers to increase the accuracy of disease diagnosis. However, high capital investments required for the discovery, development of biomarkers, and the high cost of biomarkers are restraining the growth of the biomarker technologies market.

Market Players

• Abbott Laboratories
• Agilent Technologies
• Thermo Fisher Scientific
• Roche
• Waters Corporation
• Danaher Corporation
• Shimadzu Corporation
• Danaher Corporation
• Siemens Healthcare

Market Segmentation                                                                                                                          

The global biomarker technologies market is segmented on the basis of product type, profiling technology, disease application, and research areas. Considering product type, the market is segmented into consumables, instruments, services, and software/informatics.

By profiling technology, the market is segmented into immunoassay, PCR, imaging technology, mass spectrometry, NGS, chromatography, cytogenetics, and other technologies. Based on immunoassay, the market is again segmented into ELISA, western blot, and protein microarray.